PSMA-positive metastatic castration-resistant prostate cancer research hub

PSMAfore: A phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with Progressive Metastatic Castrate Resistant Prostate Cancer

This study tests a targeted radioactive medicine called 177Lu-PSMA-617 (Pluvicto) for men with advanced prostate cancer that has spread. It compares this new therapy directly against standard hormone-blocking tablets to see which treatment is better at slowing down cancer growth before chemotherapy is needed.